Group B streptococcal antigens stimulated tumor necrosis factor alpha (TNF-␣), interleukin-1 (IL-1), and IL-6 production in human blood cultures in a concentration-and time-dependent fashion. The minimal concentrations of type-specific polysaccharides, lipoteichoic acid, and group-specific polysaccharide required to produce these effects were, respectively, 0.01, 1, and 10 g/ml. Cell separation experiments indicated that monocytes were the cell type mainly responsible for cytokine production. Time course studies indicated that TNF-␣ was released before the other cytokines. TNF-␣, however, did not appear to directly induce IL-1␤, as shown by blockade experiments with anti-TNF-␣ antibodies. IL-6 levels were moderately but significantly decreased by anti-TNF-␣. These data indicate that several products from group B streptococci are able to directly stimulate human monocytes to release TNF-␣, IL-1␤, and IL-6. These findings may be clinically relevant, since proinflammatory cytokines can mediate pathophysiologic changes during sepsis.
During invasive infections, an eccessive release of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-␣) and interleukin-1 (IL-1), can mediate severe pathophysiologic phenomena. Accordingly, TNF-␣ and IL-6 levels in adults or children with sepsis correlate with mortality rates (15, 16) . Group B streptococci (GBS) frequently cause neonatal and adult infections which are associated with high TNF-␣ and IL-6 levels in plasma (6) and are often rapidly fatal despite appropriate therapy (12) .
In neonatal rats, GBS challenge causes the production of TNF-␣, IL-1, IL-6, and gamma interferon (19) . In this model, TNF-␣ is an important pathophysiologic mediator, as evidenced by the protective effects of TNF-␣ blockade against lethality. Little is known about the ability of specific GBS components to induce cytokine production in human leukocytes. This information may be useful in developing alternative therapeutic approaches, including passive immunotherapy. In neonatal rats, heat-killed GBS or purified type-and groupspecific polysaccharides can induce TNF-␣ production and TNF-␣ dependent lethality (11) . The clinical relevance of these findings to possible species-specific differences in reactivity to bacterial products is unclear.
This led us to investigate whether TNF-␣ and other proinflammatory cytokines, such as IL-1␤ and IL-6, could be induced in human blood by the addition of purified surface components of GBS. In addition to the group-and type-specific polysaccharides, lipoteichoic acid (LTA) was tested. LTA from other gram-positive species is a potent activator of mononuclear phagocyte functions, including cytokine production (2, 10, 14, 21) .
MATERIALS AND METHODS
Streptococcal products. Group B and type Ia and III polysaccharides were extracted from strains 090R, 090, and NCTC 11080, respectively, and purified by gel filtration and anion-exchange chromatography (22) . LTA was extracted with phenol-water from supernatants of penicillin-supplemented strain 090 cultures and purified by gel filtration chromatography (13, 23) . Polysaccharides and LTA preparations contained less than 1% protein (as determined by a protein assay; Bio-Rad Laboratories, Milan, Italy) or nucleic acids (as determined by measurement of the absorbance at 260 nm). Moreover, these preparations were analyzed by high-performance anion-exchange chromatography coupled with a pulsed amperometric detector (Dionex, Sunnyvale, Calif.) (11, 22) and were considered of sufficient purity on the basis of the following observations. The weight of group B and type Ia and III polysaccharides was entirely accounted for by the component monosaccharides (88% Ϯ 5%) and relative humidity (12% Ϯ 3%). No monosaccharides, other than those expected to participate in the composition of these antigens, were detected. Purity was confirmed by showing the absence of immunological cross-reactivity with specific rabbit antisera (22) . Acylation of the LTA preparation was confirmed by a passive hemagglutination assay.
Whole-blood cultures. Blood was obtained from healthy volunteers. Plasma from each of the donors was checked by an enzyme-linked immunosorbent assay for the presence of anti-GBS antibodies. Briefly, microtiter plates were coated with type Ia (strain 1865), II (NCTC 11079), and III (COH31/rs) and unencapsulated (COH31-15) GBS and the assay was performed as previously described (18) . Only blood from donors negative for anti-GBS antibodies was used. The blood was drawn into heparinized tubes (20 U of heparin/ml), and 950 l was stimulated with 50 l of purified GBS products or heat-killed (60°C for 1 h) whole bacteria, prepared as described previously (11, 17) . RPMI culture medium and LPS from Escherichia coli O55:B5 (10 g/ml; Sigma, Milan, Italy) served as negative (unstimulated) and positive controls, respectively. Blood was incubated for 24 h on a rotator at 37°C in 5% CO 2 , and culture supernatants were stored at Ϫ20°C until tested for cytokine levels.
Isolated leukocyte cultures. Whole blood, obtained as described above, was sedimented in the presence of 5% dextran, and the leukocyte-rich plasma was centrifuged at 200 ϫ g for 10 min. The leukocytes were washed three times, resuspended in RPMI 1640 medium, and centrifuged (400 ϫ g for 30 min) over Ficoll-Hypaque (Pharmacia Biotech, Milan, Italy) gradients. Peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN) were obtained from the interface and the pellet, respectively. In further experiments, PBMC were separated in adherent and nonadherent populations by incubation in plastic tissue culture dishes for 2 h at 37°C. Adherent and nonadherent PBMC were Ͼ90% monocytes and lymphocytes, respectively, by morphology. Immunofluorescence analysis with fuorescein-conjugated polyvalent rabbit anti-human immunoglobulin G (Sigma) indicated that B cells comprised Ͻ4% of the adherent PBMC. To assess cytokine production, 2 ϫ 10 6 separated or unseparated leukocytes were cultured for 18 h in RPMI in the presence of 10% fetal bovine serum (Life Technologies, Milan, Italy) with the indicated concentrations of streptococcal components or killed bacteria.
TNF-␣ and IL-1␤ blockade. In selected experiments, we sought to assess if IL-1 or IL-6 production was the result of stimulation by other cytokines released at earlier times during culture. To this end, monocytes were cultured in the presence of anti-TNF-␣ (Genzyme, Cinisello Balsamo, Italy) or anti-IL-1␤ monoclonal antibodies. The latter was purified by affinity chromatography on Gamma bind-Sepharose (Pharmacia) from culture supernatants of hybridoma IL-B1-H6A19 cells (American Type Culture Collection). Neutralizing antibodies were added at the beginning of culture together with the stimuli.
Cytokine assays. TNF-␣, IL-1␤, and IL-6 were measured with commercial enzyme-linked immunosorbent assay kits (Quantikine; R&D Systems, Minneapolis, Minn.). The lower limits of detection were 7.5, 0.3, and 0.7 pg/ml for TNF-␣, IL-1␤, and IL-6, respectively.
Endotoxin contamination. GBS polysaccharides, monoclonal antibodies, and rabbit sera were tested for the presence of endotoxin by a Limulus amebocyte lysate assay kit (E-Toxate; Sigma). The levels of endotoxin were Ͻ0.05 ng/ml in antibody solutions and Ͻ5 pg/mg in all of the other materials.
Statistical methods. Statistical significance was assessed by one-way analysis of variance and the Student-Keuls-Newman test.
RESULTS
Cytokine production in whole blood. In the absence of stimuli, small amounts of TNF-␣, IL-1␤, and IL-6 were produced (0 to 70 pg/ml) (not shown). Polysaccharides and LTA triggered the release of all three cytokines in a dose-dependent manner (Fig. 1) . Type Ia and III polysaccharides were potent inducers, stimulating significant TNF-␣, IL-1␤, and IL-6 production even at a concentration of 0.01 g/ml. In contrast, LTA and group B polysaccharide induced cytokine responses only at Ն1 and 10 g/ml, respectively. The addition of polymyxin B (10 g/ml) or heat treatment (121°C for 20 min) of the stimuli did not affect polysaccharide-induced TNF-␣, IL-1␤, and IL-6 release, thus ruling out contamination with lipopolysaccharide or superantigenic proteins, respectively, as causes of cytokine induction (data not shown). Next, encapsulated GBS strains were compared with an unencapsulated mutant (COH31-15, provided by M. Wessels Channing Laboratories, Boston, Mass.) for their ability to induce TNF-␣, IL-1␤, and IL-6 secretion. Figure 2 shows that when 10 6 heat-killed bacteria were added per ml, there was a tendency for the unencapsulated strain to elicit lower cytokine levels than did the parental encapsulated type III (COH31/rs) strain and strains 1865 (type Ia clinical isolate) and NCTC 11079 (type II). However, these differences did not attain statistical significance due to variability in the absolute levels of cytokines produced by each of the donors.
Time course of cytokine production. Figure 3 shows the kinetics of TNF-␣, IL-1␤, and IL-6 release in whole blood stimulated with concentrations of polysaccarides and LTA that were previously found effective in inducing cytokine secretion. TNF-␣ was released at high levels as soon as 4 h after incubation of whole blood with GBS type Ia and III polysaccharides or with LTA. When triggered with group B antigen, TNF-␣ release was detectable only after 10 h. In the presence of all these stimuli, TNF-␣ levels increased until 24 h of incubation and then decreased (Fig. 3) . IL-1␤ levels increased significantly after 4 h of incubation with the type-specific polysaccharides or LTA, reached maximal values at 24 h of incubation and remained constantly elevated until the end of the experiment (46 h). When the group-specific polysaccharide was used for stimulation, a substantial release of IL-1␤ was not observed until after 7 h. IL-6 release increased throughout the incubation period after stimulation with all of the GBS components.
Leukocyte types involved in cytokine production. Cytokineproducing cells in human blood comprise granulocytes, monocytes, T and B lymphocytes, and natural killer cells. To identify the cell types which are predominantly responsible for the cytokine responses observed in whole blood, leukocytes were centrifuged over Ficoll-Hypaque gradients and PBMC were compared with PMN for their ability to produce TNF-␣, IL-1␤, or IL-6. Unseparated leukocytes, PBMC, and PMN were cultured in the presence of 25 g of type III polysaccharide, group-specific polysaccharide, or LTA. Under these conditions, PMN released lower levels of TNF-␣ than did unseparated leukocytes or PBMN, in response to any of the tested agents (Fig. 4A ). Since these data indicated that the cell populations responsible for most TNF-␣ production were contained in the PBMC fraction, the latter were further separated by adherence to plastic. Most of the TNF-␣-producing activity was found in the adherent cell population (Fig. 4B) . Similar data were obtained with IL-1␤ or IL-6 (not shown). These data indicate that monocytes are predominantly responsible for cytokine release in response to GBS components.
Effects of TNF-␣ or IL-1␤ blockade. Since TNF-␣ is able to induce other mediators (19) and since it was produced before either IL-1␤ or IL-6 (Fig. 3) , we sought to determine if TNF-␣ was responsible for the release of other cytokines in our system. Figure 5 shows that the addition of anti-TNF-␣ antibodies resulted in only partial inhibition of IL-6 release in monocyte cultures stimulated with 25 g of different streptococcal products per ml (P Ͻ 0.05). Figure 5 also shows that at this concentration, LTA stimulated significantly higher IL-6 levels than did the type III or group-specific polysaccharides. Since LTA induced less TNF-␣ than the type-specific polysaccharides (Fig. 1) , this further suggested the existence of TNF-␣-independent mechanisms leading to IL-6 production. Since IL-1 is capable of stimulating IL-6 production, the effects of anti-IL-1␤ (50 g/ml) on IL-6 levels were also investigated. However, no effects of anti-IL-1␤ were observed (not shown). Moreover, IL-1␤ levels were not significantly affected by anti-TNF-␣ (not shown).
DISCUSSION
Our results indicate that purified type-and group-specific polysaccharides and LTA from GBS, as well as whole bacterial cells, can trigger the release of TNF-␣, IL-1␤, and IL-6 in human blood cultures, a system in which many of the cellular interactions physiologically present in vivo are preserved (7, 9) . In the present study, an unencapsulated GBS mutant (COH31-15) was capable of inducing all of the cytokines tested. Similarly, this mutant strain, as well as another unencapsulated mutant, was capable of inducing TNF-␣ elevations in the plasma of neonatal rats (11) . Moreover, in two recent studies, no differences were noted between encapsulated and unencapsulated strains in their ability to induce TNF-␣ (25) or IL-6 (20) . Taken together, these data indicate that although the type-specific capsular polysaccharides may contribute to cytokine induction by whole bacteria, their presence is not obligatory for this activity. It is interesting that the kinetics of cytokine induction by the group-specific polysaccharide were markedly delayed, relative to those of the type-specific antigen or LTA. Specifically, TNF-␣, IL-1␤, or IL-6 elevations were measurable only at 7 to 10 h after the addition of the group-specific polysaccharide, while significant levels of these cytokines were already detectable at 4 h when the type-specific polysaccharides or LTA was used. These differences may reflect different mechanisms of cell activation by the group-specific polysaccharide relative to other components. Studies to further clarify this point are under way.
In the present study, purified type Ia and III polysaccharides were more effective inducers of all cytokines tested than was the group B polysaccharide in human cells. Since in neonatal rats (11) the group-specific antigen was more potent than the type III polysaccharide in inducing TNF-␣ elevations in plasma, species-specific differences appear to affect the responses to GBS components.
Although in the present study, the group-specific polysaccharide was a less effective cytokine inducer than the typespecific antigen, considerable quantities of the former are released extracellularly both in vivo (8) and in vitro (3) and could therefore play a role in stimulating cytokine release in the course of sepsis. Like LTA derived from other medically important pathogens (10), GBS LTA was shown here to elicit proinflammatory cytokines, although its potency was lower than that of the capsular polysaccharides, with the exception of IL-6 induction. Nonetheless, the maximal levels of TNF-␣, IL-1␤, and IL-6 induced by LTA were only about 50% lower than those induced by LPS, which was used as a positive control (data not shown).
Recent studies from our laboratories indicate that GBS or their products can also induce IL-8 (24), IL-10 (4), and IFN-␥ (5). Collectively, our data indicate that several GBS products can stimulate human cells to release cytokines. These components appear to be effective not only on the intact bacterial surface but also in soluble form. Both the group-and typespecific antigens are released spontaneously by GBS during infection (3, 8) , while LTA may be abundantly released by the effects of ␤-lactam antibiotics (1) . Although the exact role of these agents is still unclear, it is reasonable to hypothesize that they may act alone or synergistically to produce cytokine-mediated pathophysiologic changes in GBS disease. 
